LAC-TME分类器:基于机器学习的模型预测了清细胞脏细胞癌的生存率并优先考虑了向治疗
1Department of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Journal of cancer research and clinical oncology
|December 16, 2025
概括
一个新的机器学习模型,LAC-TME分类器,通过分析乳酸水平和瘤微环境 (TME) 来预测清细胞细胞癌 (ccRCC) 的结果. 这个工具有助于个性化治疗癌患者.
科学领域:
- 在瘤学瘤学.
- 生物信息学是一种生物信息学.
- 癌症新陈代谢 癌症新陈代谢
背景情况:
- 清细胞细胞癌 (ccRCC) 占癌的80%,晚期的存活率很低.
- 目前的ccRCC治疗受到毒性和耐药性的限制.
- 乳酸盐,通过华堡效应,创造了一个免疫抑制瘤微环境 (TME),影响治疗效率.
研究的目的:
- 开发一个机器学习分类器 (LAC-TME),将乳酸代谢和TME特征集成为ccRCC.
- 预测患者的预后,并为ccRCC个性化治疗策略.
- 研究乳酸在ccRCC中的作用及其对瘤免疫微环境的影响.
主要方法:
- 利用TCGA-KIRC和E-MTAB-1980数据集,分析基因表达,突变和临床数据.
- 采用差异表达分析,免疫透评估和101个机器学习算法.
- 整合了9个与乳酸相关的基因和TME细胞特征,以构建LAC-TME分类器.
主要成果:
- 对于ccRCC患者的存活率,LAC-TME分类器实现了高预测准确性 (C指数0.92培训,0.73验证).
- 根据乳酸和TME状态,患者被分为低/低 (最佳),高/高 (最差) 的预后组.
- 高乳酸/高TME组显示免疫抑制和免疫治疗反应不佳;LGALS1敲击抑制了ccRCC细胞生长.
结论:
- 通过整合代谢和免疫数据,LAC-TME分类器为ccRCC预后提供了一种新的方法.
- 这个分类器可以指导癌的个性化治疗决策.
- 需要进一步的临床验证来确认LAC-TME分类器在ccRCC管理中的潜力.
更多相关视频
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
8.6K
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
14.1K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Cancer Survival Analysis
629
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
629
